Lilly reveals its growth plans for the next decade

Published: 20-Dec-2001
Regulatory


Eli Lilly's strategy to discover or collaborate with partners on drug candidates with best-in-class or first-in-class potential has positioned it to become the 'pharmaceutical growth company of the decade', according to chairman, president and ceo Sidney Taurel. Its five newer products are generating outstanding growth and have significant growth potential, the company said, while five of its nine late-stage pipeline potential new products are expected to be launched between now and the end of 2002 and a further four by the end of 2004.

The late-stage pipeline includes Xigris (drotrecogin alfa [activated]), a novel biotech product for the treatment of severe sepsis. Lilly has received an approvable letter from the US FDA, with approval contingent upon successful negotiation of labelling; agreement on post-approval clinical trials; and successful completion of manufacturing inspections.

Other products are: Forteo, which has shown an ability to stimulate the growth of new, quality bone and reduce the risk of spinal and non-spinal fractures caused by osteoporosis; Cialis, a molecule being co-developed by Lilly and ICOS Corporation for the treatment of erectile dysfunction; Atomoxetine, a highly specific norepinephrine reuptake inhibitor for treating ADHD; Duloxetine for depression and for stress urinary incontinence; Olanzapine and Fluoxetine Combination (OFC) for treatment-resistant depression and psychotic depression; Alimta, for the treatment of mesothelioma; and PKC Beta Inhibitor for the treatment of diabetic macular oedema and diabetic retinopathy, the leading cause of blindness in people under the age of 65.

The company says that its drug candidates in the early-stage pipeline are equally interesting, high-potential molecules that are expected to help fuel strong, sustainable growth during the middle of the decade and beyond. 'From 2004 through to 2006, we have the potential to submit as many as 18 registration packages for new chemical entities,' said Dr August M. Watanabe, executive vice president, science and technology.

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now